Royalty Pharma RPRX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 84th percentile, 5-year average 42.1x
#2559 of 2996 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 2.6x
#4370 of 5338 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 99th percentile, 5-year average 7.1x
#4605 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 4.46 | – | 2.59 | 99% (pricier than usual) | #4370 of 5338 (1 = cheapest) |
| PE | 44.74 | 40.65 | 42.10 | 84% (pricier than usual) | #2559 of 2996 (1 = cheapest) |
| PS | 11.65 | 8.07 | 7.09 | 99% (pricier than usual) | #4605 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on RPRX.
Sign in to join the discussion.